Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice (Q41558088)

3 October 2017

1 reference

title

Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice (English)

1 reference

3 October 2017

1 reference

Freyer G

1

1 reference

3 October 2017

Ligneau B

2

1 reference

3 October 2017

Tranchand B

3

1 reference

3 October 2017

Ardiet C

4

1 reference

3 October 2017

Serre-Debeauvais F

5

1 reference

3 October 2017

Trillet-Lenoir V

6

1 reference

3 October 2017

1 May 1997

1 reference

3 October 2017

Cancer Treatment Reviews

1 reference

3 October 2017

23

1 reference

3 October 2017

153-169

1 reference

3 October 2017

3

1 reference

Pharmacokinetics in clinical practice. I. Concepts

3 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Joint NCI-EORTC consensus meeting on neoplasia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Biological age versus physical fitness age

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

The clinical pharmacology of methotrexate.new applications of an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Some suggestions for measuring predictive performance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Etoposide kinetics in patients with obstructive jaundice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Can severe vincristine neurotoxicity be prevented?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

High-dose methotrexate: a clinical and pharmacokinetic evaluation. Treatment of advanced squamous cell carcinoma of the head and neck using a prospective mathematical model and pharmacokinetic surveillance.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

1 reference

7 January 2021

Pharmacokinetic drug interactions of commonly used anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Doxorubicin clearance in the obese

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Test dose for predicting high-dose methotrexate infusions

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Limited sampling models for doxorubicin pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Methotrexate test-dose protocol in the presence of 7-hydroxy-methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Bayesian estimation and prediction of clearance in high-dose methotrexate infusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Relation of systemic exposure to unbound etoposide and hematologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Interaction of anticancer drugs with hepatic monooxygenase enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Bayesian estimation of doxorubicin pharmacokinetic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Pharmacodynamics in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

High-dose melphalan dosage adjustment: possibility of using a test-dose

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990036-0

7 January 2021

10.1016/S0305-7372(97)90036-0

Identifiers

DOI

1 reference

3 October 2017

1 reference